India Plasmid Dna Contract Manufacturing Market Size & Outlook
- HC Outsourcing
- CMO/CDMO
- Plasmid DNA Contract Manufacturing Market Outlook
- CMO/CDMO
India Plasmid Dna Contract Manufacturing Market, 2018-2030 (US$M)
Global Market
Related Markets
Ask a question about the plasmid dna contract manufacturing market
India plasmid dna contract manufacturing market highlights
- The India plasmid dna contract manufacturing market generated a revenue of USD 10.2 million in 2023 and is expected to reach USD 37.6 million by 2030.
- The India market is expected to grow at a CAGR of 20.5% from 2024 to 2030.
- In terms of segment, cell & gene therapy was the largest revenue generating application in 2023.
- Cell & Gene Therapy is the most lucrative application segment registering the fastest growth during the forecast period.
Plasmid dna contract manufacturing market data book summary
| Market revenue in 2023 | USD 10.2 million |
| Market revenue in 2030 | USD 37.6 million |
| Growth rate | 20.5% (CAGR from 2023 to 2030) |
| Largest segment | Cell & gene therapy |
| Fastest growing segment | Cell & Gene Therapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cell & Gene Therapy, Immunotherapy |
| Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
Other key industry trends
- In terms of revenue, India accounted for 3.1% of the global plasmid dna contract manufacturing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China plasmid dna contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 37.6 million by 2030.
The prevalence of chronic diseases is increasing in the country and pDNA has a wide application in the industry, which are the primary factors contributing to growth of the market. Furthermore, the wide use of pDNA in manufacturing the vaccines, especially in COVID-19 vaccines, increases the demand for the pDNA contract manufacturing market.
For instance, India approved the first COVID-19 DNA vaccine in September 2021. It is the first COVID-19 DNA vaccine ever created and was produced as a result of Mission COVID Suraksha in collaboration with DBT-BIRAC. India's ZyCoV-D immunization uses circular DNA to protect against COVID-19 infection.
The Indian government approved Zydus Cadila's DNA vaccine under emergency use authorization, citing results from phase III clinical studies that showed a roughly 66.0% efficacy for symptomatic cases. Thus, the wide use of the pDNA in vaccines & therapies is expected to drive the demand of the pDNA contract manufacturing market in the country.
No credit card required*
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Plasmid DNA Contract Manufacturing Market Scope
Plasmid DNA Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| TriLink BioTechnologies | View profile | 251-500 | San Diego, California, United States, North America | www.trilinkbiotech.com/ |
| BioCina | View profile | 101-250 | Thebarton, South Australia, Australia, Oceania | www.biocina.com/ |
| Viva Biotech | View profile | 1001-5000 | Shanghai, Shanghai, China, Asia | www.vivabiotech.com.cn/ |
| VGXI | View profile | 101-250 | The Woodlands, Texas, United States, North America | vgxii.com/ |
| PlasmidFactory | View profile | 11-50 | Bielefeld, Nordrhein-Westfalen, Germany, Europe | plasmidfactory.com/ |
| Esco Aster | View profile | 11-50 | Singapore, Central Region, Singapore, Asia | escoaster.com |
India Plasmid DNA Contract Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Plasmid DNA Contract Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Cell & Gene Therapy was the largest segment with a revenue share of 59.8% in 2023.
Horizon Databook has segmented the India plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The prevalence of chronic diseases is increasing in the country and pDNA has a wide application in the industry, which are the primary factors contributing to growth of the market. Furthermore, the wide use of pDNA in manufacturing the vaccines, especially in COVID-19 vaccines, increases the demand for the pDNA contract manufacturing market.
For instance, India approved the first COVID-19 DNA vaccine in September 2021. It is the first COVID-19 DNA vaccine ever created and was produced as a result of Mission COVID Suraksha in collaboration with DBT-BIRAC. India's ZyCoV-D immunization uses circular DNA to protect against COVID-19 infection.
The Indian government approved Zydus Cadila's DNA vaccine under emergency use authorization, citing results from phase III clinical studies that showed a roughly 66.0% efficacy for symptomatic cases. Thus, the wide use of the pDNA in vaccines & therapies is expected to drive the demand of the pDNA contract manufacturing market in the country.
- India Plasmid Dna Contract Manufacturing Market Application Outlook (Revenue, USD Million , 2018-2030)
- Cell & Gene Therapy
- Immunotherapy
- Others
- India Plasmid Dna Contract Manufacturing Market Therapeutic Area Outlook (Revenue, USD Million , 2018-2030)
- Cancer
- Infectious Diseases
- Autoimmune Diseases
- Cardiovascular Diseases
- Others
- India Plasmid Dna Contract Manufacturing Market End User Outlook (Revenue, USD Million , 2018-2030)
- Pharmaceutical and Biotechnology Companies
- Research Institutes
Reasons to subscribe to Plasmid DNA Contract Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Plasmid DNA Contract Manufacturing Market Outlook databook
- Our clientele includes a mix of Plasmid DNA Contract Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India Plasmid DNA Contract Manufacturing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into India Plasmid DNA Contract Manufacturing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
India Plasmid Dna Contract Manufacturing Market, 2018-2030 (US$M)
India plasmid dna contract manufacturing market statistics, by application, 2018-2030 (US$M)
